Advisory Advocates’s Idexx Laboratories IDXX Stock Holding History

Advisory Advocates’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-375	Closed	-$211K	–	193
2026 Q1	$211K	Sell	375 -102	-21%	-$65.4K	0.22%	144
2025 Q4	$323K	Buy	+477	New	+$325K	0.32%	109

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Advisory Advocates's IDXX Position: Q2 2026 in Review

Advisory Advocates sold out of Idexx Laboratories (IDXX) in Q2 2026, closing a stake of 375 shares — an estimated $211K sold.

Advisory Advocates first reported a position in IDXX in Q4 2025 and held it in 2 quarters. The position peaked at $323K in Q4 2025. 1,231 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Advisory Advocates reported no remaining Idexx Laboratories position as of Q2 2026 after selling out during the quarter.
Advisory Advocates sold 375 Idexx Laboratories shares in Q2 2026, an estimated $211K.
Advisory Advocates first reported a position in Idexx Laboratories in Q4 2025 and held it in 2 quarters.
Advisory Advocates's Idexx Laboratories position peaked at $323K in Q4 2025.
1,231 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Advisory Advocates's 13F filing for Q2 2026, filed 10 Aug 2026.